Collegium Pharmaceutical
Update in progressCOLL (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Collegium Pharmaceutical, Inc. is a specialty pharma company focused on developing and commercializing medicines for pain management. Its portfolio includes Jornay PM (methylphenidate HCl) for ADHD; Belbuca (buprenorphine) for chronic severe pain; Xtampza ER (abuse-deterrent oxycodone) for severe pain; Nucynta ER/IR (tapentadol) for acute and persistent pain; and Symproic (naldemedine) for opioid-induced constipation in adults with chronic non-cancer pain. Headquartered in Stoughton, MA, the company was founded in 2002 and renamed Collegium Pharmaceutical, Inc. in 2003.
Company score
- Sentiment
- 0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!